Glaxosmithkline | GSK - Current Liabilities



Glaxosmithkline reported GBP20.38B in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Amgen USD 20.48B 2.53B Jun/2025
AstraZeneca USD 33.54B 4.41B Jun/2025
Aurora Cannabis CAD 156.88M 7.07M Jun/2025
Bausch Health Companies USD 4.98B 719M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Canopy Growth CAD 98.67M 1.65M Jun/2025
Corcept Therapeutics USD 144.66M 1.6M Jun/2025
Drreddys Laboratories INR 142.59B 10.64B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
GlaxoSmithKline GBP 20.38B 453M Jun/2025
Glaxosmithkline GBP 20.38B 1.32B Jun/2025
J&J USD 56.9B 6.58B Mar/2025
Merck USD 26.04B 863M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pacira USD 313.16M 1.57M Jun/2025
Perrigo USD 1.13B 52.3M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Prestige Brands USD 109.67M 3.04M Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024
Sanofi 29.06B 3.16B Jun/2025
Supernus Pharmaceuticals USD 286.36M 4.59M Jun/2025
Takeda JPY 2.17T 336.94B Jun/2025
Teva Pharmaceutical Industries USD 11.86B 704M Jun/2025
Zoetis USD 3.37B 19M Jun/2025